Company intelligence / Profile preview

Novintethical Pharma

Lugano, Ticino, Switzerlanddevintecpharma.com ↗

Ownership: Private
Development stage: Other

Overview

Novintethical Pharma has developed several innovative medical devices for gastrointestinal and urinary health. Its lead product, Tasectan, is widely used for diarrhea management globally. The company leverages its proprietary DevinPro technology to create non-pharmaceutical solutions with proven safety and efficacy profiles. Several products have reached commercialization; others remain in clinical development.

Therapeutic areas: GastroenterologyInfectious Diseases
Modalities: Medical deviceFood supplement
Industry: Therapeutic Medical Devices

Beyond the preview

Go deeper on Novintethical Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Novintethical Pharma.

Explore the full profile